METHOD FOR DETERMINING THE SEVERITY OF NON-HEREDITARY CONNECTIVE TISSUE DYSPLASIA IN CHILDREN Russian patent published in 2022 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to pediatrics, and can be used to determine the severity of non-hereditary connective tissue dysplasia in children. The method includes analysis of the obtained blood serum samples by enzyme immunoassay, determination of the quantitative values of elastin and laminin levels in the blood serum. At levels of elastin from 7.2 ng/ml to 11.2 ng/ml and laminin from 43.4 pg/ml to 52.0 pg/ml, a mild degree of non-hereditary connective tissue dysplasia is identified. At levels of elastin from 11.3 ng/ml to 17.7 ng/ml; laminin from 52.1 pg/ml to 60.0 pg/ml, a moderate degree of non-hereditary connective tissue dysplasia is identified. At levels of elastin above 17.8 ng/ml and laminin above 61.0 pg/ml, a severe degree of non-hereditary connective tissue dysplasia is identified.

EFFECT: use of the invention ensures more accurate assessment of the severity of non-hereditary CTD in children and provides a possibility of prescribing therapy corresponding to the severity of the disease without delay.

1 cl, 5 ex